Equities research analysts predict that Amicus Therapeutics, Inc. (NASDAQ:FOLD) will announce $16.78 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Amicus Therapeutics’ earnings, with the highest sales estimate coming in at $17.30 million and the lowest estimate coming in at $16.31 million. Amicus Therapeutics posted sales of $4.17 million in the same quarter last year, which would indicate a positive year over year growth rate of 302.4%. The business is scheduled to report its next quarterly earnings report on Tuesday, May 8th.
On average, analysts expect that Amicus Therapeutics will report full-year sales of $16.78 million for the current financial year, with estimates ranging from $80.96 million to $85.74 million. For the next year, analysts forecast that the business will post sales of $161.81 million per share, with estimates ranging from $116.74 million to $200.44 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that that provide coverage for Amicus Therapeutics.
Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.11). Amicus Therapeutics had a negative net margin of 769.03% and a negative return on equity of 71.06%. The firm had revenue of $14.73 million during the quarter, compared to analysts’ expectations of $14.50 million.
In related news, SVP Daphne Quimi sold 8,000 shares of Amicus Therapeutics stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $14.72, for a total value of $117,760.00. Following the completion of the transaction, the senior vice president now directly owns 62,676 shares in the company, valued at approximately $922,590.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Bradley L. Campbell sold 32,500 shares of Amicus Therapeutics stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $15.92, for a total transaction of $517,400.00. Following the completion of the transaction, the chief operating officer now owns 186,600 shares of the company’s stock, valued at $2,970,672. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 207,870 shares of company stock valued at $3,066,112. 3.40% of the stock is currently owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in the stock. Parametric Portfolio Associates LLC bought a new position in Amicus Therapeutics in the 2nd quarter valued at $282,000. Strs Ohio bought a new position in Amicus Therapeutics in the 3rd quarter valued at $102,000. Nationwide Fund Advisors boosted its holdings in Amicus Therapeutics by 5.6% in the 3rd quarter. Nationwide Fund Advisors now owns 178,212 shares of the biopharmaceutical company’s stock valued at $2,687,000 after purchasing an additional 9,503 shares during the period. State Board of Administration of Florida Retirement System boosted its holdings in Amicus Therapeutics by 31.9% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 78,421 shares of the biopharmaceutical company’s stock valued at $1,183,000 after purchasing an additional 18,970 shares during the period. Finally, Chicago Equity Partners LLC bought a new position in Amicus Therapeutics in the 3rd quarter valued at $481,000.
Shares of Amicus Therapeutics (FOLD) traded up $0.01 during mid-day trading on Friday, hitting $15.17. 7,937,537 shares of the stock traded hands, compared to its average volume of 3,710,000. The company has a debt-to-equity ratio of 0.47, a quick ratio of 5.53 and a current ratio of 5.60. Amicus Therapeutics has a 12 month low of $6.41 and a 12 month high of $17.40. The stock has a market cap of $2,520.00, a price-to-earnings ratio of -18.06 and a beta of 1.59.
WARNING: “Amicus Therapeutics, Inc. (FOLD) Expected to Announce Quarterly Sales of $16.78 Million” was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://sportsperspectives.com/2018/03/14/amicus-therapeutics-inc-fold-expected-to-announce-quarterly-sales-of-16-78-million.html.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.